How Johnson & Johnson’s billion-dollar bet on NM26 could transform atopic dermatitis treatment

Pallavi Madhiraju- July 12, 2024 0

Johnson & Johnson (NYSE: JNJ) has successfully concluded its acquisition of Yellow Jersey, a division previously part of Numab Therapeutics, for a substantial $1.25 billion. ... Read More

Northrim Horizon acquires Noble Hospice and Palliative Care to enhance hospice services in Arizona

Pallavi Madhiraju- June 12, 2024 0

Northrim Horizon L.P., an Arizona-based permanent capital investment firm, has announced its latest strategic move with the acquisition of Noble Hospice and Palliative Care, a ... Read More

AstraZeneca secures Fusion Pharmaceuticals in $2.4bn deal to advance cancer treatment

Pallavi Madhiraju- June 6, 2024 0

AstraZeneca has finalized the acquisition of Fusion Pharmaceuticals Inc., a significant move valued at approximately $2.4 billion, designed to enhance its oncology portfolio by incorporating ... Read More

Johnson & Johnson to acquire Proteologix in $850m deal to enhance immunology portfolio

Pallavi Madhiraju- May 17, 2024 0

Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire Proteologix, Inc., a leading biotechnology company specializing in the development of bispecific ... Read More